However, although targeted therapy is very effective for HER2+ breast cancer, EC treatment achieved a better therapeutic effect than TH regimen (δV1 ≥ δV2) in approximately 25% to 33% of HER2+ patients (Table 2). Here, ERBB2 is linked to breast carcinoma.